Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.
The company primarily provides end-to-end solutions for product development and manufacturing as well as research and development (R&D) of formulations, preparation and submission of regulatory dossiers in the Indian and global markets and other testing services. The company is also engaged in the manufacture and sale of branded drugs and active pharmaceutical ingredients (APIs).
As a CDMO, the company manufactures a wide range of dosage forms including tablets, capsules, liquid medicines, vials, ampoules, blow-filled closures, topical preparations, eye drops, dry powder injections and gummy bears, to name a few.
The company has produced a total of 4,025 commercialized formulations in over 60 dosage forms. In the financial year 2023, the company manufactured formulations for 26 of the top 30 pharmaceutical companies in India in terms of revenue. For its CDMO business, the company operates 10 manufacturing units with a cumulative production capacity of 49.21 billion units annually (as of September 30, 2023).
For the year/period ended (Rs. in Cr.)
| H1FY24 | FY23 | FY22 | |
|---|---|---|---|
| Total Revenue | 4,212.21 | 3,700.93 | 3,694.52 |
| Profit After Tax | 0.79 | 97.82 | -250.87 |
| EPS | (0.28) | 6.63 | (17.65) |
| OPM (%) | 3.73% | 10.38% | (1.87%) |
| PATM (%) | 0.02% | 2.64% | (6.79%) |
For year/ period ended ( in Cr.)
| Company Name | Market Cap (Cr.) | Price | P/BV | P/E | Sales (Cr.) FY23 |
Net Profits(Cr.) FY23 |
|---|---|---|---|---|---|---|
| Akums Drugs and Pharmaceuticals Limited | 679 | 13.69 | 4,212.21 | 0.79 | ||
| Divi’s Laboratories Ltd. | 1,20,781.57 | 4,549.75 | 8.9 | 75.49 | 7,845.00 | 1,600.00 |
| Laurus Labs Ltd. | 23,315.94 | 432.45 | 5.7 | 157.32 | 5,040.83 | 168.21 |
The company is into API business. As on FY24 earnings, the IPO is aggressively priced. Hence, Investor may subscribe for long term perspective.
Never Miss IPO Investment